hematopoietic stem cell gene therapy (San Raffaele Telethon Institute for Gene Therapy/GlaxoSmithKline)

N/A

Report date: 2025/01/26 18:00:07

Base Information

Drug Namehematopoietic stem cell gene therapy (San Raffaele Telethon Institute for Gene Therapy/GlaxoSmithKline)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionNADPH Oxidase 2 inhibitors
TargetsNADPH Oxidase 2
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe San Raffaele Telethon Institute For Gene Therapy
China Registration ClassN/A

Develop Information

Active CompaniesThe San Raffaele Telethon Institute For Gene TherapyGlaxosmithkline Research & Development Ltd
Inactive CompaniesN/A
Active IndicationsGranulomatous Disease, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A